{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.05","upperLimit":"5.58","value":"3.31"},{"groupId":"OG001","lowerLimit":"3.83","upperLimit":"8.35","value":"6.09"},{"groupId":"OG002","lowerLimit":"3.43","upperLimit":"8.09","value":"5.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"331"},{"groupId":"OG001","value":"324"},{"groupId":"OG002","value":"318"}],"units":"Participants"}],"title":"Change at Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"6.64","value":"4.37"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"8.21","value":"5.96"},{"groupId":"OG002","lowerLimit":"1.92","upperLimit":"6.59","value":"4.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"337"},{"groupId":"OG002","value":"318"}],"units":"Participants"}],"title":"Change at Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.04","upperLimit":"6.58","value":"4.31"},{"groupId":"OG001","lowerLimit":"3.02","upperLimit":"7.53","value":"5.28"},{"groupId":"OG002","lowerLimit":"1.31","upperLimit":"5.99","value":"3.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"325"},{"groupId":"OG001","value":"332"},{"groupId":"OG002","value":"314"}],"units":"Participants"}],"title":"Change at Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.11","upperLimit":"5.67","value":"3.39"},{"groupId":"OG001","lowerLimit":"1.83","upperLimit":"6.36","value":"4.1"},{"groupId":"OG002","lowerLimit":"0.85","upperLimit":"5.55","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"313"},{"groupId":"OG001","value":"321"},{"groupId":"OG002","value":"301"}],"units":"Participants"}],"title":"Change at Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.11","upperLimit":"5.7","value":"3.41"},{"groupId":"OG001","lowerLimit":"1.76","upperLimit":"6.34","value":"4.05"},{"groupId":"OG002","lowerLimit":"0.74","upperLimit":"5.46","value":"3.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"285"},{"groupId":"OG002","value":"282"}],"units":"Participants"}],"title":"Change at Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.45","upperLimit":"5.07","value":"2.76"},{"groupId":"OG001","lowerLimit":"0.85","upperLimit":"5.46","value":"3.15"},{"groupId":"OG002","lowerLimit":"0.5","upperLimit":"5.26","value":"2.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"264"},{"groupId":"OG002","value":"260"}],"units":"Participants"}],"title":"Change at Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.05","upperLimit":"4.62","value":"2.29"},{"groupId":"OG001","lowerLimit":"0.81","upperLimit":"5.47","value":"3.14"},{"groupId":"OG002","lowerLimit":"0.54","upperLimit":"5.34","value":"2.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"241"},{"groupId":"OG002","value":"240"}],"units":"Participants"}],"title":"Change at Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.69","upperLimit":"4.02","value":"1.67"},{"groupId":"OG001","lowerLimit":"-0.09","upperLimit":"4.61","value":"2.26"},{"groupId":"OG002","lowerLimit":"-0.92","upperLimit":"3.91","value":"1.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"220"},{"groupId":"OG002","value":"222"}],"units":"Participants"}],"title":"Change at Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.67","upperLimit":"4.18","value":"1.75"},{"groupId":"OG001","lowerLimit":"-0.24","upperLimit":"4.53","value":"2.15"},{"groupId":"OG002","lowerLimit":"-0.73","upperLimit":"4.19","value":"1.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"192"},{"groupId":"OG002","value":"189"}],"units":"Participants"}],"title":"Change at Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.96","upperLimit":"4","value":"1.52"},{"groupId":"OG001","lowerLimit":"-0.88","upperLimit":"3.99","value":"1.56"},{"groupId":"OG002","lowerLimit":"-0.89","upperLimit":"4.12","value":"1.62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"163"}],"units":"Participants"}],"title":"Change at Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.29","upperLimit":"3","value":"0.35"},{"groupId":"OG001","lowerLimit":"0.15","upperLimit":"5.3","value":"2.72"},{"groupId":"OG002","lowerLimit":"-0.46","upperLimit":"4.84","value":"2.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"115"},{"groupId":"OG002","value":"110"}],"units":"Participants"}],"title":"Change at Cycle 11"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.7","upperLimit":"3.79","value":"1.04"},{"groupId":"OG001","lowerLimit":"0.43","upperLimit":"5.73","value":"3.08"},{"groupId":"OG002","lowerLimit":"-1.95","upperLimit":"3.46","value":"0.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"97"},{"groupId":"OG002","value":"98"}],"units":"Participants"}],"title":"Change at Cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.85","upperLimit":"5.11","value":"2.13"},{"groupId":"OG001","lowerLimit":"-0.94","upperLimit":"4.5","value":"1.78"},{"groupId":"OG002","lowerLimit":"-1.98","upperLimit":"3.62","value":"0.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"81"}],"units":"Participants"}],"title":"Change at Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.15","upperLimit":"2.89","value":"-0.13"},{"groupId":"OG001","lowerLimit":"-1.18","upperLimit":"4.36","value":"1.59"},{"groupId":"OG002","lowerLimit":"-2.95","upperLimit":"2.81","value":"-0.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"71"}],"units":"Participants"}],"title":"Change at Cycle 14"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.29","upperLimit":"1.09","value":"-2.1"},{"groupId":"OG001","lowerLimit":"-1.53","upperLimit":"4.11","value":"1.29"},{"groupId":"OG002","lowerLimit":"-1.47","upperLimit":"4.45","value":"1.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"63"}],"units":"Participants"}],"title":"Change at Cycle 15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.49","upperLimit":"0.97","value":"-2.26"},{"groupId":"OG001","lowerLimit":"-1.73","upperLimit":"4.19","value":"1.23"},{"groupId":"OG002","lowerLimit":"-1.59","upperLimit":"4.47","value":"1.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"57"}],"units":"Participants"}],"title":"Change at Cycle 16"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.38","upperLimit":"1.47","value":"-0.96"},{"groupId":"OG001","lowerLimit":"-3.66","upperLimit":"1.14","value":"-1.26"},{"groupId":"OG002","lowerLimit":"-4.11","upperLimit":"0.86","value":"-1.62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"183"},{"groupId":"OG002","value":"171"}],"units":"Participants"}],"title":"Change at Follow-up 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.56","upperLimit":"2.42","value":"-0.07"},{"groupId":"OG001","lowerLimit":"-3.65","upperLimit":"1.41","value":"-1.12"},{"groupId":"OG002","lowerLimit":"-3.62","upperLimit":"1.53","value":"-1.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"127"},{"groupId":"OG002","value":"132"}],"units":"Participants"}],"title":"Change at Follow-up 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.92","upperLimit":"2.28","value":"-0.32"},{"groupId":"OG001","lowerLimit":"-4.29","upperLimit":"0.96","value":"-1.67"},{"groupId":"OG002","lowerLimit":"-4.68","upperLimit":"0.72","value":"-1.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"101"},{"groupId":"OG002","value":"99"}],"units":"Participants"}],"title":"Change at Follow-up 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.62","upperLimit":"1.8","value":"-0.91"},{"groupId":"OG001","lowerLimit":"-5.36","upperLimit":"0.29","value":"-2.54"},{"groupId":"OG002","lowerLimit":"-3.84","upperLimit":"1.78","value":"-1.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"81"}],"units":"Participants"}],"title":"Change at Follow-up 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.99","upperLimit":"0.69","value":"-2.15"},{"groupId":"OG001","lowerLimit":"-8.27","upperLimit":"-2.44","value":"-5.36"},{"groupId":"OG002","lowerLimit":"-3.67","upperLimit":"2.02","value":"-0.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"76"}],"units":"Participants"}],"title":"Change at Follow-up 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.75","upperLimit":"1.2","value":"-1.77"},{"groupId":"OG001","lowerLimit":"-8.49","upperLimit":"-2.16","value":"-5.32"},{"groupId":"OG002","lowerLimit":"-5.82","upperLimit":"0.3","value":"-2.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"55"}],"units":"Participants"}],"title":"Change at Follow-up 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"371"},{"groupId":"OG002","value":"361"}],"units":"Participants"}],"description":"FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG002","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Analysis was performed on FACT-P population that included all participants with evaluable individual FACT-P subscale score at baseline and post-baseline on at least 1 of the subscale domains. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)","title":"Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL","type":"SECONDARY","unitOfMeasure":"units on a scale"}